|drug823||Collection of odour samples Wiki||1.00|
|drug639||COVID-19 swap test PCR Wiki||1.00|
|D009422||Nervous System Diseases NIH||0.45|
There is one clinical trial.
The purpose is to investigate the COVID-19 prevalence, associated morbidity and long-term cognitive deficits in consecutive patients presenting with acute neurological symptoms
Description: To investigate the prevalence of COVID-19 infections in consecutive patients with acute onset of neurological symptoms (with or without prior neurological disease)Measure: Prevalence of COVID-19 infection in consecutive patients with neurological symptoms Time: 6 months
Description: Three months cognitive function (Montreal Cognitive Assessment) of COVID-19 positive patients compared to COVID-19 negative patientsMeasure: Three months cognitive function of COVID-19 positive patients Time: 3 months
Description: Characterization of the neurological symptoms in neurological COVID-19 positive patients (exploratory endpoint)Measure: Clinical presentation of neurological symptoms in COVID-19 positive patients Time: 6 months
Description: Prevalence of pre-symptomatic and asymptomatic COVID-19pos in acutely admitted patients with a primary complaint of neurological symptoms.Measure: Prevalence of pre- and asymptomatic COVID-19 positive patients in acutely admitted neurological patients Time: 6 months
Description: Prevalence of anosmia in COVID-19pos patients compared to COVID-19neg patientsMeasure: Anosmia in COVID-19 positive patients Time: 6 months
Description: Neuro-specific and inflammatory blood- and cerebrospinal fluid markers in COVID-19 positive patients compared to COVID-19 negative matched controlsMeasure: Exploratory analysis on neuro-specific and inflammatory blood and cerebrospinal fluid markers of COVID-19 infection Time: 24 months
Description: Functional and immunologic plasma assays will be employed to analyze proteins and pathways in coagulation and fibrinolysisMeasure: Exploratory analysis of the coagulation profile of COVID-19 positive patients compared to COVID-19neg patients Time: 24 months
Data processed on January 01, 2021.
An HTML report was created for each of the unique drugs, MeSH, and HPO terms associated with COVID-19 clinical trials. Each report contains a list of either the drug, the MeSH terms, or the HPO terms. All of the terms in a category are displayed on the left-hand side of the report to enable easy navigation, and the reports contain a list of correlated drugs, MeSH, and HPO terms. Further, all reports contain the details of the clinical trials in which the term is referenced. Every clinical trial report shows the mapped HPO and MeSH terms, which are also hyperlinked. Related HPO terms, with their associated genes, protein mutations, and SNPs are also referenced in the report.Drug Reports MeSH Reports HPO Reports